Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Myelodysplastic syndromes.

K B Miller1

  • 1Division of Hematology/Oncology, Tufts-New England Medical Center, 750 Washington Street, Boston, MA 02111, USA.

Current Treatment Options in Oncology
|June 12, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cerebrovascular reactivity after cessation of menopausal hormone treatment.

Climacteric : the journal of the International Menopause Society·2019
Same author

Cognitive-behavioral therapy for subthreshold bulimia nervosa: A case series.

Eating and weight disorders : EWD·2012
Same author

A randomized, double-blind, placebo-controlled trial of valacyclovir prophylaxis to prevent zoster recurrence from months 4 to 24 after BMT.

Bone marrow transplantation·2010
Same author

Preservation of cocoa antioxidant activity, total polyphenols, flavan-3-ols, and procyanidin content in foods prepared with cocoa powder.

Journal of food science·2009
Same author

Blood stream infection after hematopoietic stem cell transplantation is associated with increased mortality.

Bone marrow transplantation·2007
Same author

Prospective study of extracorporeal photopheresis in steroid-refractory or steroid-resistant extensive chronic graft-versus-host disease: analysis of response and survival incorporating prognostic factors.

Bone marrow transplantation·2005
Same journal

Interaction between Regulated Cell Death Pathways and Core Cellular Processes: Unraveling the Molecular Mechanisms of Cardiotoxicity of Antitumor Drugs.

Current treatment options in oncology·2026
Same journal

Advances in Immunotherapy for Breast Cancer: Up-to-date Strategies of Immune Checkpoint Inhibitors and Therapeutic Vaccines.

Current treatment options in oncology·2026
Same journal

Recent Advances in Neoadjuvant Treatment of Anaplastic Thyroid Carcinoma: A Narrative Review.

Current treatment options in oncology·2026
Same journal

The Immunological Landscape of the Tumor Microenvironment: Implications for Immunotherapy of Unresectable and Metastatic Soft Tissue Sarcomas.

Current treatment options in oncology·2026
Same journal

Oncofertility in the Age of HER2 Blockade, Immunotherapy, PARP inhibitors, CDK4/6 inhibitors and Endocrine Treatment: Unanswered Questions in Breast Cancer.

Current treatment options in oncology·2026
Same journal

Emerging Applications of CAR-T Cell Therapy in Overcoming Resistance and Expanding Targets in Hematologic Malignancies: Insights from Recent Research.

Current treatment options in oncology·2026
See all related articles

Myelodysplastic syndromes (MDS) treatment varies by patient risk. Low-risk MDS patients receive supportive care, while high-risk patients may benefit from intensive chemotherapy or stem cell transplants.

Area of Science:

  • Hematology
  • Oncology

Background:

  • Myelodysplastic syndromes (MDS) are a diverse group of clonal hematopoietic stem cell disorders.
  • These syndromes are characterized by ineffective hematopoiesis and a significant risk of transformation to acute myeloid leukemia (AML).

Purpose of the Study:

  • To outline individualized treatment strategies for myelodysplastic syndromes based on patient-specific factors.
  • To review current therapeutic options for both low-risk and high-risk MDS patients.

Main Methods:

  • Review of current literature and clinical guidelines for MDS management.
  • Analysis of prognostic factors including age, marrow blast percentage, and cytogenetics.
  • Evaluation of treatment efficacy for various therapeutic interventions.

Related Experiment Videos

Main Results:

  • Treatment decisions for MDS should be individualized, considering age, subtype, blast percentage, and cytogenetics.
  • The International Prognostic Scoring Index (IPSI) aids in prognosis determination.
  • Supportive care is the standard for low-risk MDS; erythropoietin may benefit symptomatic anemia.
  • For high-risk MDS, options include low-dose cytarabine, amifostine, 5-azacitidine, intensive chemotherapy, or allogeneic stem cell transplant for younger patients with a suitable donor.

Conclusions:

  • Individualized treatment approaches are crucial for optimizing outcomes in myelodysplastic syndromes.
  • While some agents show response, long-term survival benefits remain limited for certain therapies in high-risk MDS.
  • Allogeneic stem cell transplantation represents a potentially curative option for eligible younger patients with high-risk MDS.